Document not yet available
ManualCOAMSDSPD1 (PD-1, CD279, PDCD1) is a CD28/CTLA-4-family type-I transmembrane inhibitory receptor induced in activated T, B, myeloid cells and thymocyte populations. It interacts with two B7 family ligands: IFN-γ-upregulated PD-L1 and DC-enriched PD-L2 found in certain tumours. PD1 ligation represses PI3K/AKT-dependent T-cell proliferation and cytokine secretion, and impairs BCR signalling through downstream transducer dephosphorylation. PD-L1-Ig inhibits anti-CD3-stimulated T-cell responses in vitro. Anti-PD1 therapeutic antibodies relieve this checkpoint-mediated suppression and are being developed for cancer immunotherapy.
| Synonyms | PD1, CD279, PD-1, PDCD1, SLEB2 |
|---|---|
| Protein Construction & Source | ·Recombinant Human (Uniprot: Q15116-1) PD1 Protein is expressed from HEK293 cells with hFc (IgG1) tag at the C-Terminus. It contains AA Pro 21 - Val 170. ·The protein has a predicted MW of 46.2 kDa. The protein migrates as 55-70 kDa when calibrated against under reducing (R) condition (SDS-PAGE) due to glycosylation. |
| Endotoxin | < 0.1 EU per ug as determined by the LAL method. |
| Purity | >90% as determined by SDS-PAGE. |
| Concentration & Formulation | ·3.01 mg/mL ·Filtered through a 0.22 μm filter, stored in 25 mM Sodium Citrate, 1x PBS, pH 7.4. |
| Transportation & Storage | ·This product is shipped under low-temperature conditions. Avoid repeated freeze-thaw cycles during handling. ·Protein solution can be stored at 2-8°C for 2-7 days. ·Samples are stable for 3 months from date of receipt at -20℃ /-80℃. ·Recommend to aliquot the protein into smaller quantities for optimal storage. |
| Target background | PD1 (PD-1, CD279, PDCD1) is a CD28/CTLA-4-family type-I transmembrane inhibitory receptor induced in activated T, B, myeloid cells and thymocyte populations. It interacts with two B7 family ligands: IFN-γ-upregulated PD-L1 and DC-enriched PD-L2 found in certain tumours. PD1 ligation represses PI3K/AKT-dependent T-cell proliferation and cytokine secretion, and impairs BCR signalling through downstream transducer dephosphorylation. PD-L1-Ig inhibits anti-CD3-stimulated T-cell responses in vitro. Anti-PD1 therapeutic antibodies relieve this checkpoint-mediated suppression and are being developed for cancer immunotherapy. |
|---|
For research use only. Not for use in diagnostic or therapeutic procedures.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.